RNA结合蛋白CSTF2通过调控MCM6促进HCC细胞的增殖和迁移

肝脏 ›› 2022, Vol. 27 ›› Issue (2): 203-209.

RNA结合蛋白CSTF2通过调控MCM6促进HCC细胞的增殖和迁移

何晓燕, 张强弩, 宰国真, 杨柳, 王桂芝

450052 河南郑州大学第五附属医院病理科(何晓燕,宰国真,杨柳,王桂芝);深圳市人民医院肝胆胰外科(张强弩)

收稿日期:2021-04-12 出版日期:2022-02-28 发布日期:2022-04-19
通讯作者: 王桂芝,Email:wgz2019@126.com

RNA-binding protein CSTF2 promotes the proliferation and migration of hepatocellular carcinoma cells by regulating MCM6

HE Xiao-yan¹, ZHANG Qiang-nu², YANG Liu¹, WANG Gui-zhi¹

1. Department of Pathology, The Fifth Affiliated Hospital of Zhengzhou University, Henan 450052, China;
2. Department of Hepatopancreatobiliary Surgery, Shenzhen People's Hospital, Guangzhou 518020, China

Received:2021-04-12 Online:2022-02-28 Published:2022-04-19
Contact: WANG Gui-zhi, Email: wgz2019@126.com

摘要/Abstract

摘要： 目的探讨CSTF2在肝细胞癌(HCC)中的临床价值及其在HCC细胞中的功能和分子机制。方法收集HCC公共数据,分析CSTF2的mRNA表达在癌组织和癌周组织中的差异。免疫组化分析CSTF2的蛋白表达在癌组织和癌周组织中的差异。分析CSTF2的表达水平与患者临床特征及预后的关系。相关性分析寻找与CSTF2存在显著相关性的基因。体外培养HCC细胞并采用体外转染过表达或siRNA的方式分别上调或下调细胞中的CSTF2及MCM6。CCK-8试验分析各组细胞的增殖情况,划痕实验分析各组细胞的转移情况。qRT-PCR和Western blot技术分析各组细胞的CSTF2及MCM6表达水平。结果 CSTF2在9个HCC的微芯片及2个HCC的RNA测序公共数据中,CSTF2均在癌组织中呈现显著上调。CSTF2的高表达预示着较低的总体生存率和无病生存率。CSTF2表达与HCC患者的肿瘤尺寸、AFP水平、TNM分期及血管侵袭等密切相关。肝癌组织中MCM6的mRNA表达与CSTF2水平呈正相关。过表达CSTF2可以促进HCC细胞的增殖和转移,同时过表达CSTF2可以上调MCM6的水平。抑制MCM6的水平可以部分消除CSTF2的促癌作用。结论 CSTF2可能通过调控MCM6在HCC中发挥促癌作用。CSTF2和MCM6可能成为HCC的潜在分子靶点。

关键词: 肝细胞癌, RNA结合蛋白, CSTF2, MCM6, 增殖, 转移

Abstract: Objective To explore the clinical significance of cleavage stimulation factor 2 (CSTF2) expresson in hepatocellular carcinoma (HCC), and its functional and molecular mechanism for the biology of HCC cells. Methods Public HCC-related datasets were collected and analyzed for the difference of CSTF2 expression between HCC and pericarcinoma tissues. Immunohistochemical analysis was used to validate the differential protein expression of CSTF2. The relationship between the expression level of CSTF2 and the clinical characteristics and prognosis of HCC patients was further analyzed. Correlation analysis was performed to identify those genes that are significantly related to CSTF2. In in vitro study, cultured HCC Cells were transfected with CSTF2 expression plasmid or MCM6 siRNA to up-regulate or down-regulate the genes' expression, respectively. CCK-8 test was used to analyze the proliferation. and wound healing assay was used to analyze the migration of HCC cells. The expression levels of CSTF2 and MCM6 in each group of cells were analyzed by qRT-PCR and western blot. Results CSTF2 was significantly up-regulated in cancer tissues in nine HCC microchips and two HCC RNA sequencing public data. High expression of CSTF2 indicated a lower overall survival rate and disease-free survival rate. The expression of CSTF2 was closely related to the tumor size, AFP level, TNM staging and vascular invasion of HCC patients. The expression of MCM6 mRNA in liver cancer tissue was positively correlated with that of CSTF2. Overexpression of CSTF2 promoted the proliferation and migration of HCC cells, and up-regulated the MCM6 level in the cells. Inhibiting the expression of MCM6 partially eliminated the cancer-promoting effect of CSTF2. Conclusion CSTF2 promotes HCC growth and metastasis via up-regulating MCM6. Both CSTF2 and MCM6 may become potential molecular targets for the treatment of HCC.

Key words: Hepatocellular carcinoma, RNA binding protein, CSTF2, MCM6, Proliferation, Migration

何晓燕, 张强弩, 宰国真, 杨柳, 王桂芝. RNA结合蛋白CSTF2通过调控MCM6促进HCC细胞的增殖和迁移[J]. 肝脏, 2022, 27(2): 203-209.

HE Xiao-yan, ZHANG Qiang-nu, YANG Liu, WANG Gui-zhi. RNA-binding protein CSTF2 promotes the proliferation and migration of hepatocellular carcinoma cells by regulating MCM6[J]. Chinese Hepatolgy, 2022, 27(2): 203-209.

参考文献

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68:394-424.
[2] Kanwal F and Singal AG, Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology, 2019, 157:54-64.
[3] Chatterji P and Rustgi AK, RNA Binding Proteins in Intestinal Epithelial Biology and Colorectal Cancer. Trends Mol Med, 2018, 24:490-506.
[4] Lujan DA, Ochoa JL, and Hartley RS, Cold-inducible RNA binding protein in cancer and inflammation. Wiley Interdiscip Rev RNA, 2018, 9.
[5] Pereira B, Billaud M, and Almeida R, RNA-Binding Proteins in Cancer: Old Players and New Actors. Trends Cancer, 2017, 3:506-528.
[6] Grozdanov PN, Masoumzadeh E, Kalscheuer VM, et al. A missense mutation in the CSTF2 gene that impairs the function of the RNA recognition motif and causes defects in 3' end processing is associated with intellectual disability in humans. Nucleic Acids Res, 2020, 48:9804-9821.
[7] Wang E, Lu SX, Pastore A, et al. Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. Cancer Cell, 2019, 35:369-384.e7.
[8] Zhao L, Cao J, Hu K, et al. RNA-binding protein RPS3 contributes to hepatocarcinogenesis by post-transcriptionally up-regulating SIRT1. Nucleic Acids Res, 2019, 47:2011-2028.
[9] Yang X, Qu S, Wang L, et al. PTBP3 splicing factor promotes hepatocellular carcinoma by destroying the splicing balance of NEAT1 and pre-miR-612. Oncogene, 2018, 37:6399-6413.
[10] Chen X, Zhang JX, Luo JH, et al. CSTF2-Induced Shortening of the RAC1 3'UTR Promotes the Pathogenesis of Urothelial Carcinoma of the Bladder. Cancer Res, 2018, 78:5848-5862.
[11] Akman HB, Oyken M, Tuncer T, et al. 3'UTR shortening and EGF signaling: implications for breast cancer. Hum Mol Genet, 2015, 24:6910-20.
[12] Liu Z, Li J, Chen J, et al. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression. BMC Cancer, 2018, 18:200.
[13] Liu M, Hu Q, Tu M, et al. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence. J Exp Clin Cancer Res, 2018, 37:10.

[1]	刘丽, 陈嘉兵, 陈成. 结肠癌肝转移应用聚乙烯醇载药微球介入栓塞的临床效果[J]. 肝脏, 2022, 27(2): 185-187.
[2]	杨怡, 席子涵, 张林颖. 极光激酶B、肿瘤蛋白53在肝细胞癌中的表达及与临床病理特征、预后的关系[J]. 肝脏, 2022, 27(2): 188-192.
[3]	张丰晓, 白雪松, 胡敬华. 终末期肝病模型评分和标准化残肝体积比预测肝细胞癌肝切除术后肝功能衰竭[J]. 肝脏, 2022, 27(2): 196-198.
[4]	季琴, 沈预程, 邵春燕. 血清PIVKA-Ⅱ和AFP-L3水平对肝细胞癌行TACE术后病情和预后评估的价值研究[J]. 肝脏, 2022, 27(2): 210-212.
[5]	王佳乐, 李琤, 李广明. lncRNA TSIX通过靶向miR-548-a-3p抑制肝细胞癌细胞增殖和侵袭的机制研究[J]. 肝脏, 2022, 27(2): 213-217.
[6]	李娇娇, 师豆豆, 黄启超, 陶梅. 长链脂酰辅酶A合成酶1在肝癌中的表达及临床意义[J]. 肝脏, 2022, 27(1): 81-85.
[7]	罗舒, 陈非, 秦蓉声, 陈英, 朱鹏. 微小RNA参与调控肝细胞癌耐药的相关研究进展[J]. 肝脏, 2022, 27(1): 116-119.
[8]	李静, 雷晓红, 茅益民. NFATc4在NASH领域的研究进展[J]. 肝脏, 2021, 26(9): 960-961.
[9]	全国多中心前瞻性肝癌极早期预警筛查项目(PreCar)专家组. 中国肝癌早筛策略专家共识[J]. 肝脏, 2021, 26(8): 825-831.
[10]	蔡思铭, 岑红霞, 廖赵妹, 陈剑标. 天冬氨酸转氨酶与血小板比值指数对早产儿肠外营养相关性胆汁淤积症的预测价值[J]. 肝脏, 2021, 26(8): 917-919.
[11]	殷霖霖, 赵思, 张秀华, 季国忠. 混合型肝细胞-胆管癌的诊疗进展[J]. 肝脏, 2021, 26(7): 720-723.
[12]	邸亮, 赵晓飞, 丁兢. 微血管侵犯对肝细胞癌根治性切除术后复发影响因素分析[J]. 肝脏, 2021, 26(6): 625-627.
[13]	李飞龙, 张子倩. 转移性肝癌合并肝性脑病短期内死亡风险的潜在影响因素研究[J]. 肝脏, 2021, 26(6): 646-649.
[14]	付豪爽, 赵爽, 谢青. 肠道菌群促进肝癌发生的机制及其临床应用[J]. 肝脏, 2021, 26(6): 696-700.
[15]	陈柳汛, 刘旭东, 张杨宇博, 郑辉, 梅浙川. 免疫检查点在肝细胞癌免疫逃逸中的作用研究进展[J]. 肝脏, 2021, 26(6): 706-708.